{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T05:25:27Z","timestamp":1740547527585,"version":"3.38.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,12,10]],"date-time":"2024-12-10T00:00:00Z","timestamp":1733788800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,12,10]],"date-time":"2024-12-10T00:00:00Z","timestamp":1733788800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Janssen Pharmaceutical K.K."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2025,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>The GVH3001 study assessed the efficacy and safety of ibrutinib in Japanese patients with steroid-dependent or -refractory chronic graft-versus-host disease (cGVHD). However, the effects of ibrutinib on lung function and reduction in corticosteroid dose, which is a measurable factor associated with improved quality of life, could not be adequately assessed in patients who initially presented with lung involvement. This <jats:italic>post hoc<\/jats:italic> analysis aimed to evaluate temporal changes in daily corticosteroid dose, as well as effectiveness outcomes based on lung function and symptom burden (percent predicted forced expiratory volume in 1 s [%FEV<jats:sub>1<\/jats:sub>] and Lee cGVHD Symptom Scale lung subscale score, respectively) in the subgroup of patients with cGVHD who had lung involvement at baseline. Seven of the 19 patients in the GVH3001 study had lung involvement at baseline. The daily corticosteroid dose for cGVHD decreased in five of these patients, and %FEV<jats:sub>1<\/jats:sub> remained relatively stable in two patients but increased to\u2009&gt;\u200980% in one patient. Lee cGVHD Symptom Scale scores were relatively stable throughout the study in patients with lung involvement. Ibrutinib may allow corticosteroid dose reduction without worsening lung function or increasing symptom burden in previously treated patients with cGVHD and associated lung involvement.<\/jats:p>","DOI":"10.1007\/s12185-024-03882-1","type":"journal-article","created":{"date-parts":[[2024,12,10]],"date-time":"2024-12-10T03:51:25Z","timestamp":1733802685000},"page":"388-396","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Temporal changes in corticosteroid dose during ibrutinib treatment in patients with cGVHD and pulmonary involvement"],"prefix":"10.1007","volume":"121","author":[{"given":"Masako","family":"Toyosaki","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinichiro","family":"Machida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daisuke","family":"Tomizawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaya","family":"Okada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masashi","family":"Sawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasunori","family":"Ueda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9391-5661","authenticated-orcid":false,"given":"Ai","family":"Omi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yosuke","family":"Koroki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takanori","family":"Teshima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,12,10]]},"reference":[{"key":"3882_CR1","doi-asserted-by":"publisher","first-page":"2565","DOI":"10.1056\/NEJMra1703472","volume":"377","author":"R Zeiser","year":"2017","unstructured":"Zeiser R, Blazar BR. Pathophysiology of chronic graft-versus-host disease and therapeutic targets. N Engl J Med. 2017;377:2565\u201379.","journal-title":"N Engl J Med"},{"key":"3882_CR2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0282753","volume":"18","author":"I Novitzky-Basso","year":"2023","unstructured":"Novitzky-Basso I, Schain F, Batyrbekova N, Webb T, Remberger M, Keating A, et al. Population-based real-world registry study to evaluate clinical outcomes of chronic graft-versus-host disease. PLoS One. 2023;18: e0282753.","journal-title":"PLoS One"},{"key":"3882_CR3","doi-asserted-by":"publisher","first-page":"504.e1","DOI":"10.1016\/j.jtct.2020.12.027","volume":"27","author":"CR Bachier","year":"2021","unstructured":"Bachier CR, Aggarwal SK, Hennegan K, Milgroom A, Francis K, Dehipawala S, et al. Epidemiology and treatment of chronic graft-versus-host disease post-allogeneic hematopoietic cell transplantation: a US claims analysis. Transplant Cell Ther. 2021;27:504.e1-04.e6.","journal-title":"Transplant Cell Ther"},{"key":"3882_CR4","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/s41409-020-0977-3","volume":"56","author":"S Pagliuca","year":"2021","unstructured":"Pagliuca S, Prata PH, Xhaard A, Frieri C, Giannoni L, Sutra Del Galy A, et al. Long-term outcomes and risk factor analysis of steroid-refractory graft versus host disease after hematopoietic stem cell transplantation. Bone Marrow Transplant. 2021;56:38\u201349.","journal-title":"Bone Marrow Transplant"},{"key":"3882_CR5","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.bbmt.2019.09.016","volume":"26","author":"C Ohwada","year":"2020","unstructured":"Ohwada C, Sakaida E, Igarashi A, Kobayashi T, Doki N, Mori T, et al. A prospective, longitudinal observation of the incidence, treatment, and survival of late acute and chronic graft-versus-host disease by National Institutes of Health criteria in a Japanese cohort. Biol Blood Marrow Transplant. 2020;26:162\u201370.","journal-title":"Biol Blood Marrow Transplant"},{"key":"3882_CR6","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1007\/s12185-020-02972-0","volume":"112","author":"Y Kuwatsuka","year":"2020","unstructured":"Kuwatsuka Y, Atsuta Y, Hirakawa A, Uchida N, Inamoto Y, Najima Y, et al. Use of unapproved or off-label drugs in Japan for the treatment of graft-versus-host disease and post-transplant viral infection. Int J Hematol. 2020;112:841\u201350.","journal-title":"Int J Hematol"},{"key":"3882_CR7","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1016\/j.bbmt.2010.06.015","volume":"16","author":"D Wolff","year":"2010","unstructured":"Wolff D, Gerbitz A, Ayuk F, Kiani A, Hildebrandt GC, Vogelsang GB, et al. Consensus conference on clinical practice in chronic graft-versus-host disease (GVHD): first-line and topical treatment of chronic GVHD. Biol Blood Marrow Transplant. 2010;16:1611\u201328.","journal-title":"Biol Blood Marrow Transplant"},{"key":"3882_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/bmt.2010.198","volume":"46","author":"BL McClune","year":"2011","unstructured":"McClune BL, Polgreen LE, Burmeister LA, Blaes AH, Mulrooney DA, Burns LJ, et al. Screening, prevention and management of osteoporosis and bone loss in adult and pediatric hematopoietic cell transplant recipients. Bone Marrow Transplant. 2011;46:1\u20139.","journal-title":"Bone Marrow Transplant"},{"key":"3882_CR9","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1016\/j.bbmt.2016.02.020","volume":"22","author":"Y Matsumura-Kimoto","year":"2016","unstructured":"Matsumura-Kimoto Y, Inamoto Y, Tajima K, Kawajiri A, Tanaka T, Hirakawa T, et al. Association of cumulative steroid dose with risk of infection after treatment for severe acute graft-versus-host disease. Biol Blood Marrow Transplant. 2016;22:1102\u20137.","journal-title":"Biol Blood Marrow Transplant"},{"key":"3882_CR10","first-page":"30","volume":"9","author":"D Liu","year":"2013","unstructured":"Liu D, Ahmet A, Ward L, Krishnamoorthy P, Mandelcorn ED, Leigh R, et al. A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy. AACI. 2013;9:30.","journal-title":"AACI"},{"key":"3882_CR11","doi-asserted-by":"publisher","first-page":"8671.e1","DOI":"10.1016\/j.jtct.2021.05.019","volume":"27","author":"N Doki","year":"2021","unstructured":"Doki N, Toyosaki M, Shiratori S, Osumi T, Okada M, Kawakita T, et al. An open-label, single-arm, multicenter study of ibrutinib in Japanese patients with steroid-dependent\/refractory chronic graft-versus-host disease. Transplant Cell Ther. 2021;27:8671.e1-e9.","journal-title":"Transplant Cell Ther"},{"key":"3882_CR12","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1097\/MOH.0000000000000026","volume":"21","author":"SM Jaglowski","year":"2014","unstructured":"Jaglowski SM, Devine SM. Graft-versus-host disease: why have we not made more progress? Curr Opin Hematol. 2014;21:141\u20137.","journal-title":"Curr Opin Hematol"},{"key":"3882_CR13","first-page":"104","volume":"6","author":"M Toyosaki","year":"2023","unstructured":"Toyosaki M, Doki N, Shiratori S, Osumi T, Okada M, Kawakita T, et al. Long-term use of ibrutinib in Japanese patients with steroid dependent\/refractory cGVHD: final analysis of multicenter study. Blood Cell Therapy. 2023;6:104\u201313.","journal-title":"Blood Cell Therapy"},{"key":"3882_CR14","doi-asserted-by":"publisher","first-page":"2002","DOI":"10.1016\/j.bbmt.2019.06.023","volume":"25","author":"EK Waller","year":"2019","unstructured":"Waller EK, Miklos D, Cutler C, Arora M, Jagasia MH, Pusic I, et al. Ibrutinib for chronic graft-versus-host disease after failure of prior therapy: 1-year update of a phase 1b\/2 study. Biol Blood Marrow Transplant. 2019;25:2002\u20137.","journal-title":"Biol Blood Marrow Transplant"},{"key":"3882_CR15","doi-asserted-by":"publisher","first-page":"2243","DOI":"10.1182\/blood-2017-07-793786","volume":"130","author":"D Miklos","year":"2017","unstructured":"Miklos D, Cutler CS, Arora M, Waller EK, Jagasia M, Pusic I, et al. Ibrutinib for chronic graft-versus-host disease after failure of prior therapy. Blood. 2017;130:2243\u201350.","journal-title":"Blood"},{"key":"3882_CR16","doi-asserted-by":"publisher","first-page":"4867","DOI":"10.1172\/JCI75328","volume":"124","author":"JA Dubovsky","year":"2014","unstructured":"Dubovsky JA, Flynn R, Du J, Harrington BK, Zhong Y, Kaffenberger B, et al. Ibrutinib treatment ameliorates murine chronic graft-versus-host disease. J Clin Invest. 2014;124:4867\u201376.","journal-title":"J Clin Invest"},{"key":"3882_CR17","doi-asserted-by":"publisher","first-page":"2012","DOI":"10.1182\/bloodadvances.2018013060","volume":"2","author":"SM Jaglowski","year":"2018","unstructured":"Jaglowski SM, Blazar BR. How ibrutinib, a B-cell malignancy drug, became an FDA-approved second-line therapy for steroid-resistant chronic GVHD. Blood Adv. 2018;2:2012\u20139.","journal-title":"Blood Adv"},{"key":"3882_CR18","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.bbmt.2014.12.001","volume":"21","author":"MH Jagasia","year":"2015","unstructured":"Jagasia MH, Greinix HT, Arora M, Williams KM, Wolff D, Cowen EW, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. The 2014 Diagnosis and Staging Working Group report. Biol Blood Marrow Transplant. 2015;21:389-401.e1.","journal-title":"Biol Blood Marrow Transplant"},{"key":"3882_CR19","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/j.healun.2019.03.009","volume":"38","author":"GM Verleden","year":"2019","unstructured":"Verleden GM, Glanville AR, Lease ED, Fisher AJ, Calabrese F, Corris PA, et al. Chronic lung allograft dysfunction: definition, diagnostic criteria, and approaches to treatment-A consensus report from the Pulmonary Council of the ISHLT. J Heart Lung Transplant. 2019;38:493\u2013503.","journal-title":"J Heart Lung Transplant"},{"key":"3882_CR20","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1097\/TP.0b013e318277e29e","volume":"95","author":"UM Vogl","year":"2013","unstructured":"Vogl UM, Nagayama K, Bojic M, Hoda MA, Klepetko W, Jaksch P, et al. Lung transplantation for bronchiolitis obliterans after allogeneic hematopoietic stem cell transplantation: a single-center experience. Transplantation. 2013;95:623\u20138.","journal-title":"Transplantation"},{"key":"3882_CR21","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1016\/j.bbmt.2015.02.025","volume":"21","author":"SJ Lee","year":"2015","unstructured":"Lee SJ, Wolff D, Kitko C, Koreth J, Inamoto Y, Jagasia M, et al. Measuring therapeutic response in chronic graft-versus-host disease. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: IV. The 2014 Response Criteria Working Group report. Biol Blood Marrow Transplant. 2015;21:984\u201399.","journal-title":"Biol Blood Marrow Transplant"},{"key":"3882_CR22","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1016\/j.bbmt.2015.02.025","volume":"21","author":"SJ Lee","year":"2015","unstructured":"Lee SJ, Wolff D, Kitko C, Koreth J, Inamoto Y, Jagasia M, et al. Measuring therapeutic response in chronic graft-versus-host disease. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: IV. The 2014 Response Criteria Working Group report. Biol Blood Marrow Transplant. 2015;21:984\u201399.","journal-title":"Biol Blood Marrow Transplant"},{"key":"3882_CR23","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1053\/bbmt.2002.v8.pm12234170","volume":"8","author":"S Lee","year":"2002","unstructured":"Lee S, Cook EF, Soiffer R, Antin JH. Development and validation of a scale to measure symptoms of chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2002;8:444\u201352.","journal-title":"Biol Blood Marrow Transplant"},{"key":"3882_CR24","doi-asserted-by":"publisher","first-page":"9901.e1","DOI":"10.1016\/j.jtct.2021.08.017","volume":"27","author":"KK Chin","year":"2021","unstructured":"Chin KK, Kim HT, Inyang EA, Ho V, Koreth J, Romee R, et al. Ibrutinib in steroid-refractory chronic graft-versus-host disease, a single-center experience. Transplant Cell Ther. 2021;27:9901.e1-e7.","journal-title":"Transplant Cell Ther"},{"key":"3882_CR25","doi-asserted-by":"publisher","first-page":"4532","DOI":"10.1182\/blood-2019-129171","volume":"134","author":"S Singhal","year":"2019","unstructured":"Singhal S, Brondstetter T, Miklos DB, Tierney DK, Hsu J, Chhatwani L. Ibrutinib for chronic pulmonary graft-versus-host-disease after progression on prior therapy. Blood. 2019;134:4532.","journal-title":"Blood"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-024-03882-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-024-03882-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-024-03882-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T12:42:43Z","timestamp":1740487363000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-024-03882-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,10]]},"references-count":25,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["3882"],"URL":"https:\/\/doi.org\/10.1007\/s12185-024-03882-1","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"type":"print","value":"0925-5710"},{"type":"electronic","value":"1865-3774"}],"subject":[],"published":{"date-parts":[[2024,12,10]]},"assertion":[{"value":"13 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 December 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Masako Toyosaki and Shinichiro Machida have received honoraria for lectures from Janssen Pharmaceutical K.K. Daisuke Tomizawa has received honoraria for lectures from AbbVie Inc., Amgen Inc., Astellas Pharma Inc., Chugai Pharmaceutical Co., Ltd., Meiji Seika Pharmatech Co., Ltd., Miyarisan Pharmaceutical Co., Ltd., Nihon Servier Co., Ltd., Nippon Shinyaku Co., Ltd., Novartis Pharma K.K., Otsuka Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd. and Taiho Pharmaceutical Co., Ltd.; has received consulting fees from Amgen Inc.; and has served on advisory boards for Meiji Seika Pharmatech Co., Ltd. and Novartis Pharma K.K. Masaya Okada has no conflicts of interest to declare. Masashi Sawa has received honoraria for lectures from AbbVie, Amgen, Asahi Kasei Corporation, Astellas Pharma Inc., AstraZeneca K.K., Bristol-Myers Squibb K.K., Chugai Pharmaceutical Co., Ltd., CSL Behring K.K., Daiichi Sankyo Co., Ltd., Eisai Co. Ltd., Janssen Pharmaceutical K.K., Kyowa Kirin Co., Ltd., MSD, Mundipharma K.K., Nippon Kayaku Co., Ltd., Nippon Shinyaku Co., Ltd., Novartis Pharma K.K., Novo Nordisk Pharma Ltd., Ono Pharmaceutical Co., Ltd., Otsuka Pharmaceutical Co., Ltd, Pfizer, Sanofi K.K., Sumitomo Pharma Co., Ltd., SymBio Pharmaceuticals Ltd. and Takeda Pharmaceutical Co., Ltd. Yasunori Ueda has received honoraria for lectures and has served on advisory boards for Sanofi K.K. Ai Omi and Yosuke Koroki are employees of Janssen Pharmaceutical K.K. Yosuke Koroki owns employee stocks at Johnson & Johnson. Takanori Teshima is the President of the Japanese Society for Transplantation and Cellular Therapy, and the Director of the Japanese Society of Hematology and the Japan Society of Transfusion Medicine and Cell Therapy; has received grants for research from Asahi Kasei Pharma Corporation, Chugai Pharmaceutical Co., Ltd., Eisai Co., Ltd., Fuji Pharma Co., Ltd., Kyowa Kirin Co., Ltd., Nippon Shinyaku Co., Ltd., Ono Pharmaceutical Co., Ltd., Shionogi & Co., Ltd., and Sumitomo Pharma Co., Ltd.; has received contracts for clinical trials from Astellas Pharma Inc. and Otsuka Pharmaceutical Co., Ltd.; has received honoraria for lectures from Astellas Pharma Inc., AbbVie GK, Bristol-Myers Squibb K.K., Chugai Pharmaceutical Co., Ltd., Janssen Pharmaceutical K.K., Kyowa Kirin Co., Ltd., Merck & Co., Inc., Nippon Shinyaku Co., Ltd., Novartis Pharma K.K. and Sumitomo Pharma Co., Ltd.; and has received consulting fees from Kyowa Kirin Co., Ltd., Meiji Seika Pharma Co., Ltd., Nippon Shinyaku Co., Ltd. and Otsuka Pharmaceutical Co., Ltd.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}